UTHR
United Therapeutics Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+47/100
Last price
541.62
▲ 5.22 (0.97%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
538.00
Prev close
536.40
Day high
546.16
Day low
527.36
Volume
1.21M
Market cap
$23.23B
P/E (TTM)
19.40
52W range
409.07 – 609.35
Day trading desk
Gap from prior close
+0.30%
Prior close 536.40
VWAP
540.42
+0.22% from price
Relative volume
1.88×
Unusually busy
Session range
3.79%
526.20 – 546.16
Position in range
77%
Near session high
ATR (14D)
21.64
4.00% of price
Prior day high
547.98
PDH
Prior day low
535.53
PDL
Bid / ask spread
—
Quote not published
Session volume
1.21M
Avg 644.08K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+12.49%
+10.5%
1M
+11.08%
+9.9%
3M
-2.29%
-6.8%
6M
-4.26%
-22.4%
YTD
+11.16%
-3.1%
1Y
+19.54%
+3.1%
3Y
+139.79%
+57.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on UTHR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+16.18K
Net buying
Buy transactions
163
1.47M shares
Sell transactions
158
1.45M shares
Net transactions
+321
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
859.10K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 2, 26 | ROTHBLATT MARTINE A Chief Executive Officer |
CONVERSION | 9.50K | $1.12M | Indirect |
| Oct 2, 26 | ROTHBLATT MARTINE A Chief Executive Officer |
SELL | 9.50K | $5.22M | Indirect |
| Oct 1, 26 | MAHON PAUL A General Counsel |
CONVERSION | 8.30K | $1.21M | Direct |
| Oct 1, 26 | MAHON PAUL A General Counsel |
SELL | 8.30K | $4.69M | Direct |
| Sep 30, 26 | ROTHBLATT MARTINE A Chief Executive Officer |
CONVERSION | 9.50K | $1.12M | Indirect |
| Sep 30, 26 | ROTHBLATT MARTINE A Chief Executive Officer |
SELL | 7.58K | $3.93M | Indirect |
| Sep 30, 26 | ROTHBLATT MARTINE A Chief Executive Officer |
SELL | 1.92K | $1.06M | Indirect |
| Sep 29, 26 | ROTHBLATT MARTINE A Chief Executive Officer |
CONVERSION | 9.50K | $1.12M | Indirect |
| Sep 29, 26 | ROTHBLATT MARTINE A Chief Executive Officer |
SELL | 9.50K | $4.54M | Indirect |
| Sep 28, 26 | ROTHBLATT MARTINE A Chief Executive Officer |
CONVERSION | 9.50K | $1.12M | Indirect |
| Sep 28, 26 | ROTHBLATT MARTINE A Chief Executive Officer |
SELL | 9.50K | $4.57M | Indirect |
| Sep 25, 26 | ROTHBLATT MARTINE A Chief Executive Officer |
CONVERSION | 9.50K | $1.12M | Indirect |
| Sep 25, 26 | ROTHBLATT MARTINE A Chief Executive Officer |
SELL | 9.50K | $4.52M | Indirect |
| Sep 23, 26 | ROTHBLATT MARTINE A Chief Executive Officer |
CONVERSION | 9.50K | $1.12M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BENKOWITZ MICHAEL |
President | — | Conversion of Exercise of derivative security |
CAUSEY CHRISTOPHER |
Director | 4.19K | Conversion of Exercise of derivative security |
EDGEMOND JAMES C. |
Chief Financial Officer | 18.88K | Conversion of Exercise of derivative security |
GILTNER RICHARD A |
Director | 21.88K | Conversion of Exercise of derivative security |
KURZWEIL RAYMOND C |
Director | 13.32K | Conversion of Exercise of derivative security |
MAHON PAUL A |
General Counsel | 45.17K | Conversion of Exercise of derivative security |
MESA NILDA |
Director | 5.58K | Conversion of Exercise of derivative security |
OLIAN JUDY D. |
Director | 5.55K | Conversion of Exercise of derivative security |
ROTHBLATT MARTINE A |
Chief Executive Officer | — | Conversion of Exercise of derivative security |
THOMPSON TOMMY G |
Director | 22.48K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$23.23B
Enterprise value$20.57B
Revenue (TTM)$3.15B
Gross profit$2.72B
EBITDA$1.50B
Net income$1.31B
EPS (TTM)$27.92
Free cash flow$557.14M
Total cash$2.66B
Total debt$0
Book value / share$149.97
Shares outstanding42.89M
Float39.21M
Short % of float7.62%
Dividend yield0.00%
Beta (5Y)0.49
Valuation & profitability ratios
Trailing P/E19.40
Forward P/E17.81
PEG ratio2.22
Price / sales—
Price / book3.61
EV / revenue6.52
EV / EBITDA13.75
Gross margin86.14%
Operating margin42.23%
Profit margin41.56%
Return on equity19.31%
Return on assets11.61%
Debt / equity—
Current ratio5.73
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $3.18B | $2.88B | $2.33B | $1.94B | +10.6% |
| Operating revenue | $3.18B | $2.88B | $2.33B | $1.94B | +10.6% |
| Cost of revenue | $384.40M | $309.70M | $257.50M | $151.60M | +24.1% |
| Gross profit | $2.80B | $2.57B | $2.07B | $1.78B | +9.0% |
| Research & development | $550.00M | $481.00M | $408.00M | $322.90M | +14.3% |
| Selling, general & admin | $731.10M | $638.60M | $477.10M | $482.10M | +14.5% |
| Total operating expense | $1.28B | $1.12B | $885.10M | $805.00M | +14.4% |
| Operating income | $1.52B | $1.45B | $1.18B | $979.70M | +4.8% |
| Net interest income | $172.50M | $156.20M | $103.40M | $12.80M | +10.4% |
| Pre-tax income | $1.71B | $1.54B | $1.27B | $950.60M | +11.4% |
| Tax provision | $379.20M | $343.90M | $289.50M | $223.30M | +10.3% |
| Net income | $1.33B | $1.20B | $984.80M | $727.30M | +11.7% |
| Net income to common | $1.33B | $1.20B | $984.80M | $727.30M | +11.7% |
| Basic EPS | 30.13 | 26.44 | 21.04 | 15.98 | +14.0% |
| Diluted EPS | 27.86 | 24.64 | 19.81 | 15.00 | +13.1% |
| EBIT | $1.73B | $1.58B | $1.33B | $983.00M | +9.6% |
| EBITDA | $1.82B | $1.65B | $1.39B | $1.03B | +9.9% |
| Basic shares | 44.30M | 45.20M | 46.80M | 45.50M | -2.0% |
| Diluted shares | 47.90M | 48.50M | 49.70M | 48.50M | -1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.56B | $1.70B | $1.21B | $961.20M | — | -8.3% |
| Accounts receivable | $350.20M | $279.30M | $278.90M | $220.40M | — | +25.4% |
| Inventory | $183.10M | $157.90M | $111.80M | $102.00M | — | +16.0% |
| Total current assets | $3.70B | $3.87B | $3.55B | $3.38B | — | -4.4% |
| Property, plant & equipment | $1.73B | $1.22B | $1.05B | $861.50M | — | +41.5% |
| Goodwill & intangibles | $116.50M | $111.90M | $114.20M | $44.50M | — | +4.1% |
| Total assets | $7.88B | $7.36B | $7.17B | $6.04B | — | +7.0% |
| Total current liabilities | $560.60M | $738.10M | $804.40M | $343.20M | — | -24.0% |
| Current debt | — | $300.00M | $400.00M | — | — | — |
| Long-term debt | — | — | $300.00M | $800.00M | $800.00M | — |
| Total debt | — | $300.00M | $700.00M | $800.00M | $800.00M | — |
| Total liabilities | $783.80M | $920.00M | $1.18B | $1.25B | — | -14.8% |
| Retained earnings | $8.56B | $7.22B | $6.03B | $5.04B | — | +18.5% |
| Shareholder equity | $7.10B | $6.44B | $5.98B | $4.80B | — | +10.1% |
| Working capital | $3.14B | $3.14B | $2.75B | $3.04B | — | +0.2% |
| Net tangible assets | $6.98B | $6.33B | $5.87B | $4.75B | — | +10.2% |
| Shares issued | 76.45M | 75.00M | 73.66M | 72.65M | — | +1.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $1.33B | $1.20B | $984.80M | $727.30M | +11.7% |
| Depreciation & amortisation | $85.60M | $72.50M | $53.20M | $51.30M | +18.1% |
| Stock-based compensation | $147.70M | $144.00M | $39.10M | $106.80M | +2.6% |
| Change in working capital | -$106.50M | $3.90M | -$33.40M | -$141.20M | -2,830.8% |
| Operating cash flow | $1.56B | $1.33B | $978.00M | $802.50M | +17.6% |
| Capital expenditure | -$526.00M | -$246.50M | -$230.40M | -$138.80M | -113.4% |
| Investing cash flow | -$551.30M | $417.20M | -$719.60M | -$811.50M | -232.1% |
| Share buybacks | -$1.02B | -$1.01B | -$13.80M | -$11.40M | -0.4% |
| Financing cash flow | -$1.15B | -$1.25B | -$11.90M | $75.40M | +8.4% |
| Free cash flow | $1.04B | $1.08B | $747.60M | $663.70M | -4.2% |
| End cash position | $1.56B | $1.70B | $1.21B | $961.20M | -8.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $783.30M | $781.50M | $790.20M | $799.50M | $798.60M | +0.2% |
| Operating revenue | $776.50M | $776.20M | $807.60M | $792.60M | $793.10M | +0.0% |
| Cost of revenue | $99.50M | $133.40M | $103.40M | $100.90M | $87.60M | -25.4% |
| Gross profit | $683.80M | $648.10M | $686.80M | $698.60M | $711.00M | +5.5% |
| Research & development | $146.30M | $138.20M | $139.50M | $127.50M | $134.00M | +5.9% |
| Selling, general & admin | $206.70M | $184.10M | $189.80M | $181.80M | $190.80M | +12.3% |
| Total operating expense | $353.00M | $322.30M | $329.30M | $309.30M | $324.80M | +9.5% |
| Operating income | $330.80M | $325.80M | $357.50M | $389.30M | $386.20M | +1.5% |
| Net interest income | $28.60M | $38.80M | $40.10M | $43.40M | $44.00M | -26.3% |
| Pre-tax income | $372.70M | $318.30M | $444.00M | $438.00M | $408.40M | +17.1% |
| Tax provision | $39.70M | $43.40M | $79.70M | $99.30M | $98.90M | -8.5% |
| Net income | $333.00M | $274.90M | $364.30M | $338.70M | $309.50M | +21.1% |
| Net income to common | $333.00M | $274.90M | $364.30M | $338.70M | $309.50M | +21.1% |
| Basic EPS | 7.82 | 6.32 | 8.41 | 7.73 | 6.86 | +23.7% |
| Diluted EPS | 7.27 | 5.82 | 7.70 | 7.16 | 6.41 | +24.9% |
| EBIT | $375.60M | $321.30M | $447.10M | $441.00M | $415.70M | +16.9% |
| EBITDA | $399.80M | $343.90M | $469.90M | $462.90M | $436.80M | +16.3% |
| Basic shares | 42.60M | 43.50M | 43.30M | 43.80M | 45.10M | -2.1% |
| Diluted shares | 45.80M | 47.20M | 47.30M | 47.30M | 48.30M | -3.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.80B | $1.28B | $1.56B | $1.34B | $1.59B | — | +40.9% |
| Cash & short-term investments | $2.66B | $2.15B | $2.92B | $2.77B | $3.05B | — | +23.6% |
| Accounts receivable | $310.30M | $312.00M | $350.20M | $297.70M | $379.30M | — | -0.5% |
| Inventory | $193.80M | $178.30M | $183.10M | $176.50M | $169.20M | — | +8.7% |
| Total current assets | $3.48B | $2.87B | $3.70B | $3.49B | $3.83B | — | +21.3% |
| Property, plant & equipment | $1.93B | $1.84B | $1.73B | $1.56B | $1.36B | — | +4.9% |
| Goodwill & intangibles | $114.10M | $115.50M | $116.50M | $116.70M | $111.50M | — | -1.2% |
| Total assets | $7.22B | $6.71B | $7.88B | $7.35B | $7.91B | — | +7.5% |
| Total current liabilities | $607.80M | $599.10M | $560.60M | $546.30M | $527.10M | — | +1.5% |
| Current debt | — | — | — | — | — | $200.00M | — |
| Total debt | — | — | — | — | — | $200.00M | — |
| Total liabilities | $819.80M | $813.10M | $783.80M | $760.90M | $734.40M | — | +0.8% |
| Retained earnings | $9.16B | $8.83B | $8.56B | $8.19B | $7.85B | — | +3.8% |
| Shareholder equity | $6.40B | $5.90B | $7.10B | $6.59B | $7.17B | — | +8.5% |
| Working capital | $2.88B | $2.27B | $3.14B | $2.95B | $3.30B | — | +26.5% |
| Net tangible assets | $6.29B | $5.79B | $6.98B | $6.47B | $7.06B | — | +8.7% |
| Shares issued | 42.68M | 77.13M | 76.45M | 75.71M | 75.38M | — | -44.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $333.00M | $274.90M | $364.30M | $338.70M | $309.50M | +21.1% |
| Depreciation & amortisation | $24.20M | $22.60M | $22.80M | $21.90M | $21.10M | +7.1% |
| Stock-based compensation | $43.40M | $33.90M | $39.00M | $39.10M | $37.80M | +28.0% |
| Change in working capital | -$124.10M | $12.40M | -$144.00M | $162.50M | -$203.00M | -1,100.8% |
| Operating cash flow | $313.60M | $463.30M | $346.20M | $562.10M | $191.70M | -32.3% |
| Capital expenditure | -$108.00M | -$100.80M | -$172.90M | -$216.00M | -$62.20M | -7.1% |
| Investing cash flow | $87.50M | $743.70M | -$227.60M | $140.90M | -$299.90M | -88.2% |
| Share buybacks | -$58.80M | -$1.50B | $4.40M | -$1.00B | -$20.50M | +96.1% |
| Financing cash flow | $122.40M | -$1.48B | $98.40M | -$956.00M | -$198.60M | +108.2% |
| Free cash flow | $205.60M | $362.50M | $173.30M | $346.10M | $129.50M | -43.3% |
| End cash position | $1.80B | $1.28B | $1.56B | $1.34B | $1.59B | +40.9% |
Options analytics
Put / call volume
0.69
Call-heavy session
Put / call open interest
0.93
Positioning, not flow
Max pain
510.00
-5.8% from spot
ATM implied vol
45.3%
Nearest strike to spot
Skew (10% OTM)
-1.4%
Calls bid over puts
Call volume
166
Contracts, this expiry
Put volume
115
Contracts, this expiry
Heaviest call OI
540.00
8.38K contracts
Heaviest put OI
460.00
8.31K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 6.86 | 7.27 | +5.9% |
| Mar 2026 | 6.86 | 5.82 | -15.1% |
| Dec 2025 | 6.76 | 7.70 | +14.0% |
| Sep 2025 | 6.96 | 7.16 | +2.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 6.40 | 13 | $785.91M | -1.7% |
| Next quarter | 6.82 | 13 | $802.81M | +1.6% |
| Current year | 26.17 | 14 | $3.15B | -1.0% |
| Next year | 29.16 | 14 | $3.49B | +10.7% |
Analyst targets & ownership
Mean target$646.00
High target$728.00
Low target$321.00
Implied upside19.27%
Analyst count14
ConsensusBUY
Strong buy / Buy3 / 8
Hold3
Sell / Strong sell1 / 0
Held by insiders2.00%
Held by institutions99.97%
Institutions holding1.21K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
513.71
+5.43% from price
SMA 20
506.45
+6.94% from price
SMA 50
511.54
+5.88% from price
SMA 100
529.82
+2.23% from price
SMA 200
525.67
+3.03% from price
EMA 12
520.81
+4.00% from price
EMA 26
512.87
+5.60% from price
EMA 50
515.11
+5.15% from price
RSI (14)
59.5
Neutral
MACD (12,26,9)
7.93
Hist 7.20
ATR (14)
21.64
4.00% of price
Realised vol 30D
46.8%
Annualised
Bollinger upper
557.48
20, 2σ
Bollinger lower
455.42
20, 2σ
50 / 200 cross
Death
511.54 vs 525.67
Trend bias
Above 200
+3.03%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.21
Less volatile than market
Correlation to SPY
0.08
Largely independent
Realised vol 30D
46.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-20.9%
Peak to trough
Max drawdown 5Y
-33.0%
Peak to trough
ATR 14
21.64
4.00% of price
Beta (reported)
0.49
5Y monthly, from filing
Short interest
Shares short
2.80M
Prior 2.11M
Change vs prior
+32.6%
Shorts adding
% of float
7.62%
Normal
% of shares out
6.53%
Against total outstanding
Days to cover
4.9
Liquid
Float
39.21M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | BTIG | UPGRADE | Neutral | Buy |
| Sep 24, 26 | Goldman Sachs | INITIATED | — | Sell |
| Aug 6, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 23, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jul 10, 26 | B of A Securities | MAINTAINED | Neutral | Neutral |
| Jul 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| May 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| May 7, 26 | Wells Fargo | UPGRADE | Equal-Weight | Overweight |
| Apr 10, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Mar 31, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 31, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Mar 31, 26 | B of A Securities | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split2:1
Split dateSep 23, 2009
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-08
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-07-23
Offering Registrations
S-8 POS · 2026-07-13
Corporate Changes & Voting Matters
8-K · 2026-06-29
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-06-02
Corporate Changes & Voting Matters
8-K · 2026-05-06
Annual Report to Shareholders
ARS · 2026-04-29
Headlines
United Therapeutics Insider Sold Shares Worth $5,145,537, According to a Recent SEC Filing
MT Newswires · 7h ago
United Therapeutics Insider Sold Shares Worth $5,219,015, According to a Recent SEC Filing
MT Newswires · 1d ago
Stocktwits Wall Street Wrap: Analysts Turn Bullish On Sweetgreen, Target And Airbnb – Liquidia And FICO Face Downgrades
Stocktwits · 5d ago
United Therapeutics Insider Sold Shares Worth $3,926,177, According to a Recent SEC Filing
MT Newswires · 5d ago
United Therapeutics Insider Sold Shares Worth $1,056,425, According to a Recent SEC Filing
MT Newswires · 5d ago
United Therapeutics Just Sent Liquidia Stock Lower After Patent Battle
Barchart · 5d ago
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
StockStory · 5d ago
Liquidia Shares Drop After Downgrades From Raymond James, BTIG
MT Newswires · 5d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.